Oncology is the medical specialty concerned with cancer, including its biology, diagnosis, staging, treatment, surveillance, supportive care, and prevention. Cancer comprises a large and diverse group of diseases in which cells acquire abnormal growth, survival, invasion, or dissemination characteristics through genetic and epigenetic changes. Oncology therefore cannot be understood as a single disease category because cancers arising in different tissues have distinct molecular profiles, natural histories, treatment sensitivities, and prognostic factors.
Major therapeutic modalities include surgery, radiotherapy, systemic drug treatment, immunotherapy, targeted therapy, hormone therapy, cellular therapy, and combinations of these approaches. Medical oncologists frequently coordinate multidisciplinary care involving surgeons, pathologists, radiologists, radiation oncologists, specialist nurses, geneticists, pharmacists, and palliative-care professionals. Treatment objectives can include cure, long-term disease control, reduction of recurrence risk, symptom relief, or preservation of function, depending on cancer type and clinical circumstances.
The history of Oncology reflects progressive changes in understanding cancer from an anatomical disease to a molecularly heterogeneous group of disorders. Early cancer treatment relied substantially on surgery, but advances in anaesthesia, antisepsis, pathology, and surgical technique made increasingly extensive operations possible. Radiotherapy emerged after the discovery of X-rays and radioactivity, while cytotoxic chemotherapy developed particularly during the twentieth century and demonstrated that systemic treatment could control disseminated disease.
The identification of oncogenic viruses, tumour suppressor genes, oncogenes, DNA-repair mechanisms, and signalling pathways subsequently established cancer as fundamentally a disease of altered cellular regulation. Molecular classification has since transformed several tumour types, allowing therapies to target specific genetic or biochemical abnormalities. Immunotherapy further demonstrated that the immune system can be harnessed to recognise and attack malignant cells. Contemporary Oncology therefore combines population-level cancer prevention with highly specialised molecular and individualised treatment.
Cancer development, or carcinogenesis, generally involves the accumulation of alterations that disrupt normal controls over cell proliferation, differentiation, DNA repair, apoptosis, metabolism, and interactions with surrounding tissues. These alterations may arise from inherited susceptibility, environmental exposures, endogenous biological processes, or random replication-associated events. Important cancer-associated exposures include tobacco smoke, ultraviolet radiation, certain infections, alcohol, ionising radiation, and specific occupational or environmental carcinogens, although risk varies by cancer type.
Cancer cells can evade growth suppression, resist cell death, stimulate blood-vessel formation, alter metabolism, invade surrounding tissues, and disseminate to distant organs. The tumour microenvironment includes immune cells, fibroblasts, blood vessels, extracellular matrix, and signalling molecules that can influence tumour behaviour. Metastasis occurs through a multistep process involving invasion, entry into circulation, survival during transit, exit into distant tissue, and establishment of a secondary tumour.
Diagnosis and staging are fundamental components of Oncology. Diagnosis generally requires pathological confirmation through examination of tissue or cells, although exact methods vary by cancer. Pathologists determine tumour type, grade, molecular characteristics, and other features relevant to treatment. Staging describes the anatomical extent of disease and commonly evaluates the primary tumour, regional lymph nodes, and distant metastases, often using the TNM framework for solid tumours.
Imaging modalities such as CT, MRI, ultrasound, PET, and nuclear medicine studies provide complementary information about tumour location and spread. Molecular tests can identify mutations, gene amplifications, rearrangements, mismatch-repair abnormalities, or other biomarkers that predict response to specific treatments. Biomarkers may be diagnostic, prognostic, or predictive, and these categories should not be confused. A prognostic marker provides information about likely disease behaviour, whereas a predictive marker helps indicate the likelihood of benefit from a particular treatment.
Surgery remains central to the treatment of many solid tumours and can be curative when disease is localised and complete removal is technically and biologically appropriate. Radiotherapy uses ionising radiation to damage cancer-cell DNA and can be delivered externally or internally through techniques such as brachytherapy. Systemic Oncology includes chemotherapy, endocrine therapy, targeted agents, immunotherapy, and other drugs capable of reaching cancer cells throughout the body.
Conventional cytotoxic chemotherapy often affects rapidly dividing cells, explaining adverse effects involving tissues such as bone marrow, gastrointestinal epithelium, and hair follicles. Targeted therapies are designed to interfere with specific molecular dependencies, while endocrine therapies exploit hormone dependence in cancers such as certain breast and prostate cancers. Immunotherapies can activate or redirect immune responses against malignant cells, but their effectiveness depends strongly on tumour biology and immune context.
Precision Oncology uses molecular information to refine treatment selection. Examples include targeting specific kinase alterations, hormone receptors, DNA-repair defects, or immune-regulatory pathways. Some tumours develop resistance through secondary mutations, pathway bypass mechanisms, changes in tumour-cell phenotype, or alterations in the tumour microenvironment. Resistance may be present before treatment or emerge under therapeutic selection pressure. Combination therapy can sometimes prevent or delay resistance, but combinations may also increase toxicity and complexity.
Pharmacogenomics can influence treatment in selected circumstances by identifying inherited or tumour-associated genetic factors affecting drug metabolism, toxicity, or response. Liquid biopsy approaches analyse tumour-derived material, including circulating tumour DNA, and may provide information without conventional tissue sampling, although their clinical applications vary by cancer and test. Precision treatment therefore depends not simply on sequencing a tumour but on interpreting molecular findings in the context of validated clinical evidence and the characteristics of the individual cancer.
Supportive and palliative Oncology addresses the consequences of cancer and its treatment regardless of whether treatment intent is curative or disease-controlling. Symptoms can include pain, breathlessness, nausea, fatigue, anorexia, bowel disturbance, neurological problems, and psychological distress. Supportive treatment may involve antiemetics, analgesia, transfusion, nutritional support, infection management, treatment of treatment-related complications, bone-strengthening approaches, and management of cancer-related metabolic abnormalities. Palliative care focuses on quality of life and relief of suffering and can be provided alongside active anticancer treatment.
End-of-life care is one component of palliative medicine rather than a synonym for all palliative care. Survivorship care addresses long-term effects after cancer treatment, including recurrence surveillance, cardiovascular or endocrine consequences, fertility issues, psychological effects, neuropathy, fatigue, and second malignancies. Oncology therefore extends beyond tumour eradication to the full trajectory of living with and after cancer.
Cancer prevention and early detection are major population-level components of Oncology. Tobacco control substantially reduces risk of multiple cancers, while vaccination against oncogenic infections such as human papillomavirus and hepatitis B can prevent certain cancers. Sun protection reduces ultraviolet exposure and can lower risk of some skin cancers. Screening programmes aim to detect specified cancers or precancerous abnormalities before they become symptomatic, but screening tests have limitations involving false positives, false negatives, overdiagnosis, and unequal participation.
Genetic counselling and testing can identify inherited cancer-predisposition syndromes in selected individuals and families, allowing tailored surveillance or preventive interventions. Modern cancer research increasingly combines epidemiology, molecular biology, immunology, genomics, imaging, computational analysis, and clinical trials. Because cancer encompasses many distinct diseases, accurate Oncology requires disease-specific evidence rather than assuming that a treatment or outcome observed in one cancer type applies universally to all malignancies.
